Summit Partners Public Asset Management LLC Purchases 20,521 Shares of Natera, Inc. (NASDAQ:NTRA)

Summit Partners Public Asset Management LLC boosted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 584,726 shares of the medical research company’s stock after acquiring an additional 20,521 shares during the period. Natera accounts for 2.3% of Summit Partners Public Asset Management LLC’s investment portfolio, making the stock its 7th biggest holding. Summit Partners Public Asset Management LLC owned approximately 0.47% of Natera worth $74,231,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. O Shaughnessy Asset Management LLC bought a new stake in shares of Natera in the first quarter valued at approximately $220,000. Kennedy Capital Management LLC bought a new stake in Natera in the 1st quarter valued at $292,000. Comerica Bank grew its position in Natera by 458.0% in the 1st quarter. Comerica Bank now owns 14,866 shares of the medical research company’s stock worth $1,360,000 after purchasing an additional 12,202 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Natera during the 1st quarter worth about $707,000. Finally, Cetera Investment Advisers raised its position in shares of Natera by 514.9% during the first quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company’s stock valued at $1,802,000 after buying an additional 16,496 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NTRA. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Robert W. Baird boosted their price objective on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley boosted their price target on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Craig Hallum raised their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $140.59.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 9,682 shares of Natera stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total value of $1,548,926.36. Following the completion of the sale, the director now directly owns 9,704 shares of the company’s stock, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,503 shares of company stock worth $6,325,804. 7.60% of the stock is currently owned by corporate insiders.

Natera Price Performance

NASDAQ NTRA opened at $168.45 on Friday. The stock’s 50 day simple moving average is $133.88 and its 200 day simple moving average is $119.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $53.88 and a one year high of $171.95.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. Sell-side analysts anticipate that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.